Performance of the systemic lupus erythematosus risk probability index in a cohort of undifferentiated connective tissue disease.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
30 08 2022
Historique:
received: 05 10 2021
revised: 20 12 2021
pubmed: 12 1 2022
medline: 9 9 2022
entrez: 11 1 2022
Statut: ppublish

Résumé

We sought to evaluate the performance of the SLE Risk Probability Index (SLERPI) for identification of SLE in a large cohort of patients with UCTD. The SLERPI was applied in a cohort of patients who met classification criteria for UCTD and did not fulfil any classification criteria for other defined CTD including SLE. Patients with a SLERPI score of >7 were 'diagnosed' as SLE. Patients diagnosed with SLE and those not were compared in terms of disease characteristics and index parameters. A total of 422 patients with UCTD were included in the study. Median (interquartile range) SLERPI was 4.25 (2.5) points, while 39 (9.2%) patients had a SLERPI score >7 and were diagnosed as SLE. Patients with younger age (P = 0.026) and presence of malar rash (P < 0.0001), mucosal ulcer (P < 0.0001), alopecia (P < 0.0001), ANA positivity (P < 0.0001), low C3 and C4 (P = 0.002), proteinuria >500 mg/24 h (P = 0.001), thrombocytopenia (P = 0.009) or autoimmune haemolytic anaemia (P < 0.0001) were more likely to fulfil criteria for SLE by the SLERPI. SLERPI enabled a significant proportion of patients to be identified as SLE in our UCTD cohort. This new probability index may be useful for early identification of SLE among patients with signs of CTD without fulfilling any definite criteria set.

Identifiants

pubmed: 35015853
pii: 6500274
doi: 10.1093/rheumatology/keac005
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3606-3613

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Abdulsamet Erden (A)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Hakan Apaydın (H)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Antonis Fanouriakis (A)

Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens.
Rheumatology, 'Asklepieion' General Hospital, Athens, Greece.

Serdar Can Güven (SC)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Berkan Armagan (B)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Pınar Akyüz Dağlı (P)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Hatice Ecem Konak (HE)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Bünyamin Polat (B)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Ebru Atalar (E)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Serdar Esmer (S)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Özlem Karakaş (Ö)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Bahar Özdemir (B)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Mehmet Akif Eksin (MA)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Ahmet Omma (A)

Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Orhan Kücüksahin (O)

Division of Rheumatology, Department of Internal Medicine, Ankara City Hospital, Yıldırım Beyazıt University, Ankara, Turkey.

George K Bertsias (GK)

Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine.
Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Crete.

Dimitrios T Boumpas (DT)

Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens.
Laboratory of Immune Regulation and Tolerance, Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH